Experience with application of nasal interferon in the treatment and prevention of acute respiratory infections

Authors

  • S.A. Kramarov MD, PhD, Head of the Department of Pediatric Infectious Diseases, Bogomolets National Medical University, Kyiv, Ukraine,
  • V.V. Yevtushenko PhD, Associate Professor at the Department of Pediatric Infectious Diseases, Bogomolets National Medical University, Kyiv, Ukraine,

DOI:

https://doi.org/10.22141/2312-413x.7.4.2019.178883

Keywords:

acute respiratory viral infections, interferons, treatment, prevention

Abstract

According to the World Health Organization data, every third inhabitant of the planet annually seeks medical care for acute respiratory infection. The results of many studies indicate that the correction of immune processes in the site of inflammation is more effective than the impact on the immune cells of blood stream (in systemic use of medications). Therefore, a logical approach to the treatment of respiratory viral infections affecting the respiratory epithelium is the use of intranasal interferon drugs that provide antiviral, immunomodulatory and antibacterial action in the site of infection. In the available literature, there are a sufficient number of clinical studies dealing with the efficacy of nasal and aerosol forms of interferon alpha in acute respiratory viral infections (ARVI). They demonstrated that recombinant interferon alpha is an effective drug for the treatment and prevention of ARVI. Its use reduces the period of clinical recovery of patients, the severity of clinical symptoms of the disease, makes it possible to avoid manifestation of disease. Also, interferon preparations can be used as agents for the prevention of influenza and ARVI.

References

Башкина О.А., Афанасьев С.С., Алешкин В.А. и др. Эффект лечения рецидивирующего бронхита у детей комбинированными интерфероновыми препаратами при различных путях аппликации. Журнал микробиологии, эпидемиологии и иммунобиологии. 2005. 3. 99-102.

Буряк В.Н., Такташов С.И., Махмутов Р.Ф., Пошехонова Ю.В., Шабан Н.И., Моисеева Т.Ю. Клинико-патогенетические аспекты и оптимизация терапевтических подходов при острых респираторно-вирусных инфекциях у детей. Современная педиатрия. 2014. 4(60). 72-75.

Дворецкий Л.И., Полевщиков А.В., Соколов А.С. Эффективность противовоспалительной терапии при ОРВИ у взрослых в амбулаторной практике: результаты программы «Эскулап». Consilium medicum. 2006. 106. 20-25.

Ершов Ф.И., Киселев О.И. Интерфероны и их индукторы (от молекул до лекарств). М.: ГЭОТАР, 2005. С. 212-277.

Киселев О.И., Васильева И.А. Современные средства патогенетической и симптоматической терапии гриппа и ОРЗ. Русский медицинский журнал. 2004. 12(2). 91-93.

Крамарєв С.О., Євтушенко В.В. Оцінка ефективності рекомбінантного інтерферону альфа для профілактики та лікування гострих респіраторних вірусних інфекцій і грипу в дітей. Сімейна медицина. 2008. 4. 19-22.

Крамарєв С.О., Мальцев В.І., Казимирко В.К. Грипферон як ефективний засіб профілактики та лікування грипу й інших ГРВІ. Інфекційні хвороби. 2003. 1. 22-24.

Кривопустов С.П. Интраназальное применение рекомбинантного интерферона альфа в педиатрии. Здоров’я України. 2010. 32.

Кузнецов В.П. Человеческие интерфероны: биологические свойства, опыт профилактического и лечебного применения. Острые респираторные заболевания у детей: Сб. научных трудов. 1986. 71-78.

Лиманская А.Ю., Давыдова Ю.В. Препараты интерферона в лечении острых респираторных вирусных инфекций у беременных группы высокого риска. Здоровье женщины. 2015. 9(105). 74-76.

Москалюк В.Д. Лаферон у комплексному лікуванні хворих на грип А. Інфекційні хвороби. 2004. 1. 32-34.

Образцова Е.В., Осидак Л.В., Афанасьева О.И. и др. Препараты рекомбинантного интерферона альфа-2 в лечении острых респираторных инфекций. Детские инфекции. 2005. 2. 46-50.

Посисеева Л.В., Васильева Т.П., Чумаков А.С. Интерферонопрофилактика на этапе подготовки и во время беременности. Акушерство и гинекология. 2014. 7. 74-78.

Сысоева Г.М., Масычева В.И., Даниленко Е.Д. Перспективы использования индукторов интерферона в лечении и профилактике гриппа и ОРВИ. Вестник Российской академии медицинских наук. 2004. 11. 33-38.

Феклисова Л., Шебекова В., Целипанова Е., Михайлова Н., Гапонюк П. Гриппферон у детей, больных ОРВИ. Врач. 2001. 3. 40-41.

Юлиш Е.И., Чернышева О.Е., Сорока Ю. и др. Интерферонотерапия при ОРВИ у детей. Здоров’я України. 2011. 4. 72-73.

Baron S., Tyring S.K., Fleischmann W.R. et al. The interferons. Mechanisms of action and clinical applications. JAMA. 1991. 266. 1375-1383.

Cantell K. Development of antiviral therapy with alpha interferons: promisese, false hopes and accomplishments. Ann. Med. 1995. 27. 23-28.

Hayden F.G., Albrecht J.K., Kaiser D.L. et al. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N. Engl. J. Med. 1986. 314. 71-75.

Herzong C., Berger R., Fernex M. et al. Intranasal interferon (rIFN-alpha A, Ro 22-8181) for contact prophylaxis against common cold: a randomized, double-blind and placebo-controlled filed study. Antiviral Res. 1986. 6. 171-176.

José R.J. Respiratory infections: a global burden. Ann. Res Hosp.. 2018 [cited 2019 Sep 15]. 2. 12. URL: http://arh.amegroups.com/article/view/4514/5468.

Kneyber M.C., Moll H.A., Groot R. Treatment and prevention of respiratory virus infection. Eur. J. Pediatr. 2000. 159. 399-411.

Meshcheriakova A.K., Kostinov M.P., Magarshak O.O., Guseva T.S., Parshina O.V. The influence of gel-like recombinant interferon α-2b on the clinical course of acute respiratory infection and the state of mucosal immunity in the pregnant women. Vestn. Otorinolaringol. 2014. (6). 50-3.

Tregoning J.S., Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin. Microbiol. Rev. American Society for Microbiology (ASM); 2010 [cited 2019 Sep 15]. 23. 74-98. URL: http://www.ncbi.nlm.nih.gov/pubmed/20065326.

Xi Y., Day S.L., Jackson R.J., Ranasinghe C. Role of novel type I interferon epsilon in viral infection and mucosal immunity. Mucos. Immunol. 2012. Vol. 23 [Epub].

Yu D., Chen Q., Zhang L. et al. A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005. 19(3). 216-9.

Downloads

Published

2019-08-01

Issue

Vol. 7 No. 4 (2019)

Section

Original Researches

License

Copyright (c) 2019 ACTUAL INFECTOLOGY

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our edition uses the copyright terms of Creative Commons for open access journals.

Authors, who are published in this journal, agree with the following terms:

  1. The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
  2. Directing  the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
  3. The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
  4. The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
  5. The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
  6. The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
  7. The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.